

Table S1. Total cost, effectiveness and incremental cost-effectiveness ratio of routine GM surveillance compared to no monitoring in patients receiving non-mould-active prophylaxis.

Strategy	Total Cost	Incremental Cost	QALY Gained	Incremental QALY	ICER #
Routine GM assay during non-mould-active prophylaxis	SGD 12,225 (USD 8989)	-	5.3053	-	
No GM assay during non-mould-active prophylaxis	SGD 15,294 (USD 11,246)	SGD 3069 (USD 2257)	5.3029	-0.0024	dominated

ICER: incremental cost-effectiveness ratio, GM: galactomannan, QALY: quality-adjusted life-year. #A dominated strategy is more costly and less effective relative to its comparator.